Palivizumab Pregnancy and Breastfeeding Warnings
Brand names: Synagis
Medically reviewed by Drugs.com. Last updated on Dec 1, 2023.
Palivizumab Pregnancy Warnings
Animal studies have not been reported. There are no controlled data in human pregnancy.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
This drug is not indicated for adult use.
AU TGA pregnancy category: Not assigned
US FDA pregnancy category: C
Comment:
-It is not known whether this drug can cause fetal harm when administered to a pregnant woman or could affect reproductive capacity.
Palivizumab Breastfeeding Warnings
The manufacturer makes no recommendation regarding use during lactation.
Excreted into human milk: Unknown
Excreted into animal milk: Unknown
Comments:
-This drug is not indicated for adult use.
-The effects in the nursing infant are unknown.
See also
References for pregnancy information
- Product Information. Synagis (palivizumab). Ross Product Division Pharmaceuticals. 2001;PROD.
- Cerner Multum, Inc. UK Summary of Product Characteristics.
- Cerner Multum, Inc. Australian Product Information.
References for breastfeeding information
- Product Information. Synagis (palivizumab). Ross Product Division Pharmaceuticals. 2001;PROD.
- Cerner Multum, Inc. UK Summary of Product Characteristics.
- Cerner Multum, Inc. Australian Product Information.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
